Genetic mutations and abnormal gene regulation are key mechanisms underlying
tumorigenesis. Nucleosomes, which consist of DNA wrapped around histone cores …

Dysregulation of histone deacetylases (HDACs) is closely related to tumor development and
progression. As promising anticancer targets, HDACs have gained a great deal of research …

Over the last several decades, it has become clear that epigenetic abnormalities may be one
of the hallmarks of cancer. Posttranslational modifications of histones, for example, may play …

The high mobility group protein 2 (HMGA2) regulates gene expression by binding to AT-rich
regions of DNA. Akin to other DNA architectural proteins, HMGA2 is highly expressed in …

Inhibitors of histone deacetylases (HDACs) are nowadays part of the therapeutic arsenal
mainly against cancers, with four compounds approved by the Food and Drug …

Deregulation of protein post-translational modifications is intensively involved in the etiology
of diseases, including degenerative diseases, inflammatory injuries, and cancers …

The high mobility group A2 (HMGA2) protein is a non‑histone architectural transcription
factor that modulates the transcription of several genes by binding to AT‑rich sequences in …

Over decades of studies, accumulating evidence has suggested that epigenetic
dysregulation is a hallmark of tumours. Post-translational modifications of histones are …

Cholangiocarcinoma (CCA) is a highly invasive and metastatic form of carcinoma with bleak
prognosis due to limited therapies, frequent relapse, and chemotherapy resistance. There is …

Recent studies highlight the great potential impact of HDAC inhibitors (HDACis) in
suppressing TNBC, even though clinical trials including a single HDACis demonstrated …